Free Trial
TSE:MDP

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Medexus Pharmaceuticals logo
C$2.43
+0.05 (+2.10%)
(As of 11/1/2024 ET)

About Medexus Pharmaceuticals Stock (TSE:MDP)

Key Stats

Today's Range
C$2.38
C$2.44
50-Day Range
C$2.33
C$2.73
52-Week Range
C$1.44
C$3.16
Volume
9,972 shs
Average Volume
40,814 shs
Market Capitalization
C$59.61 million
P/E Ratio
48.60
Dividend Yield
N/A
Price Target
C$5.88
Consensus Rating
Strong Buy

Company Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Medexus Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
46th Percentile Overall Score

MDP MarketRank™: 

Medexus Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medexus Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Medexus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Medexus Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medexus Pharmaceuticals is 48.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.95.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medexus Pharmaceuticals is 48.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.37.

  • Price to Book Value per Share Ratio

    Medexus Pharmaceuticals has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Medexus Pharmaceuticals' valuation and earnings.
  • Short Interest

    There is no current short interest data available for MDP.
  • Dividend Yield

    Medexus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Medexus Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MDP.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Medexus Pharmaceuticals this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$10,916.00 in company stock and sold C$0.00 in company stock.

  • Percentage Held by Insiders

    Only 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.

  • Read more about Medexus Pharmaceuticals' insider trading history.
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDP Stock News Headlines

Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc (P731.BE)
See More Headlines

MDP Stock Analysis - Frequently Asked Questions

Medexus Pharmaceuticals' stock was trading at C$2.47 at the beginning of 2024. Since then, MDP shares have decreased by 1.6% and is now trading at C$2.43.
View the best growth stocks for 2024 here
.

Medexus Pharmaceuticals Inc. (TSE:MDP) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.07. The firm earned $37.33 million during the quarter, compared to analysts' expectations of $36.95 million. Medexus Pharmaceuticals had a net margin of 1.00% and a trailing twelve-month return on equity of 3.95%.

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS).

Company Calendar

Last Earnings
8/07/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/07/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
98
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$5.88
High Stock Price Target
C$8.25
Low Stock Price Target
C$3.50
Potential Upside/Downside
+141.8%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
4 Analysts

Profitability

Net Income
C$1.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$108.78 million
Book Value
C$1.33 per share

Miscellaneous

Free Float
N/A
Market Cap
C$59.61 million
Optionable
Not Optionable
Beta
1.96
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (TSE:MDP) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners